PharmaMar’s lurbinectedin led to complete or partial tumor regression in more than a third of study participants with small-cell lung cancer (SCLC) who had received at least one prior treatment for the disease. ...
19 junio 2019
TREATMENT NEWS . Lurbinectedin Yields Favorable Outcomes in Those With Small-Cell Lung Cancer .
PharmaMar’s lurbinectedin led to complete or partial tumor regression in more than a third of study participants with small-cell lung cancer (SCLC) who had received at least one prior treatment for the disease. ...